Intrinsic rifamycin resistance ofMycobacterium abscessusis mediated by ADP-ribosyltransferase MAB_0591 | Zendy

Anna Rominski | Zendy; Anna Roditscheff | Zendy; Petra Selchow | Zendy; Erik C. Böttger | Zendy; Peter Sander | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intrinsic rifamycin resistance ofMycobacterium abscessusis mediated by ADP-ribosyltransferase MAB_0591

Author(s) -

Anna Rominski,

Anna Roditscheff,

Petra Selchow,

Erik C. Böttger,

Peter Sander

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw466

Subject(s) - rifamycin , mycobacterium abscessus , microbiology and biotechnology , rifampicin , mycobacterium tuberculosis , biology , antibacterial agent , rpob , rifabutin , mycobacterium , antibiotics , medicine , tuberculosis , genetics , bacteria , clarithromycin , pathology

Rifampicin, a potent first-line TB drug of the rifamycin group, shows only little activity against the emerging pathogen Mycobacterium abscessus. Reportedly, bacterial resistance to rifampicin is associated with polymorphisms in the target gene rpoB or the presence of enzymes that modify and thereby inactivate rifampicin. The aim of this study was to investigate the role of the MAB_0591 (arr Mab )-encoded rifampicin ADP-ribosyltransferase (Arr_Mab) in innate high-level rifampicin resistance in M. abscessus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research